Protocol Number: 00-C-0080
Patients 18 years or older with testosterone-dependent prostate cancer that has persisted or recurred after having had surgery, radiation therapy, or cryosurgery, but whose disease has not metastasized (spread beyond the prostate) may be eligible for this study. Candidates are screened with a medical history and physical examination, including blood tests, bone and CT scans or other imaging studies.
Study participants are randomly assigned to one of two treatment groups. One group receives leuprolide or goserelin followed by thalidomide; the other receives leuprolide or goserelin followed by placebo (a look-alike pill with no active ingredients). Patients in both groups receive an injection of leuprolide or goserelin once a month for 6 months. After that time they take four capsules of either thalidomide or placebo once a day and remain on the drug until their prostate-specific antigen (PSA) level returns to what it was before beginning leuprolide or goserelin or to 5 nanograms per liter, whichever is lower. (PSA is a protein secreted by the prostate gland. Monitoring changes in levels of this protein can help evaluate tumor progression.) At this point the entire procedure begins again, starting with leuprolide or goserelin treatment, but the experimental drug is switched; patients originally treated with thalidomide are crossed over to placebo, and patients originally treated with placebo are crossed over to thalidomide. Patients are monitored periodically with the following tests and procedures: -Medical histories and physical examinations -Blood and urine tests to monitor thalidomide and PSA levels, the response to treatment, and routine laboratory values (e.g., cell counts and kidney and liver function) -CT and bone scans, and possibly other imaging tests to assess the tumor -Electromyography (EMG) and nerve conduction studies, as needed. For electromyography, a thin needle is inserted into a few muscles and the patient is asked to relax or to contract the muscles. The electrical activity of the muscle cells is recorded and analyzed by a computer. For nerve conduction testing, nerves are stimulated with brief electrical shocks through small metal electrodes attached to the skin and the conduction of the shocks is recorded and analyzed. Patients whose PSA level rises while on leuprolide or goserelin or never falls below 5 ng/ml, or who develop metastatic disease are taken off the study. Patients whose disease recurs after the second treatment are taken off the study and may receive standard treatments from their doctor or enroll in another NCI treatment study, if an appropriate study is available.
Search The Studies | Help | Questions |
National Institutes of Health Clinical Center |
||